Starpharma today released its Appendix 4C - Quarterly Cashflow Report for the period ended 31 March 2013.

Starpharma today announced it has been granted three new patents by the United States Patent and Trademark Office (USPTO) which strengthen and expand the Company’s patent estate for its drug delivery platform.

In addition, China’s patent office has also informed the Company that it has allowed a similarly broad, drug delivery-related patent.

ABC News’ The Business Presenter Ticky Fullerton interviewed Starpharma CEO Dr Jackie Fairley on Thursday 4^th April 2013. Ticky discussed the positive results of Starpharma’s Phase 2 prevention of recurrence BV trials.

 Read the Transcrip (external link)

AAP business reporter Trevor Chappell investigates Starpharma’s positive results for its Phase II trial of VivaGel to prevent recurring bacterial vaginosis (R-BV). The results demonstrated a reduced overall risk of R-BV.

"The commercial opportunity for recurrent BV is very attractive, with an estimated market of more than $1 billion," said Starpharma CEO Dr Jackie Fairley.

 Go to the article (external link)

Starpharma  today announced the positive results of its exploratory Phase 2 study of VivaGel^® for the prevention of recurrent bacterial vaginosis (R-BV).  The results showed a reduced overall risk of R-BV during the study in patients using 1% VivaGel^® and time to first recurrence was delayed compared with placebo.